Sugi Predict

Sugi Predict / Compounds / SCHEMBL3280209

SCHEMBL3280209

SCHEMBL3280209

CCc1cn(S(=O)(=O)c2ccc(C)cc2)c2nc(Cl)nc(Nc3ccc4cn[nH]c4c3)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.41
▸ MEN1 O00255 5/20 0.41
▸ CYP1A2 P05177 2/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ KDM4E B2RXH2 5/20 0.38
▸ MAPT P10636 5/20 0.38
▸ ALDH1A1 P00352 5/20 0.38
▸ HTT P42858 3/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ MCL1 Q07820 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ USP2 O75604 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3279013 0.91 KMT2A (0.44) KMT2AMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL3280540 0.90 KMT2A (0.42) KMT2AMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL3280105 0.87 KMT2A (0.41) KMT2AMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL3279022 0.82 KMT2A (0.44) KMT2AMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL13387117 0.76 EGFR (0.41) KMT2AMEN1PDGFRBPDGFRACLK2
SCHEMBL3282602 0.72 SYK (0.58) PDGFRBPDGFRACLK2PRKXCLK4
SCHEMBL1020660 0.72 HDAC1 (0.36) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL14666837 0.71 HDAC1 (0.40) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL1018097 0.70 MAPT (0.44) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL3280304 0.69 KDR (0.43) KMT2AMEN1KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 — — US disclosed
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 — — US disclosed
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 — — US disclosed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — WO disclosed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — WO disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — US disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — US disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054425-A1 PROTEIN KINASE INHIBITORS SYK, JAK2, BTK KMT2A 1401/4885MEN1 3684/4885CYP1A2 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.